Birinapant

also known as TL32711

Developed for: cancer · acute myeloid leukemia · malignant epithelial tumor of ovary · cancer of unknown primary site · chronic hepatitis B virus infection · fallopian tube cancer · fallopian tube neoplasm · fallopian tube serous adenocarcinoma
+8 more
· myelodysplastic syndrome · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · ovarian serous adenocarcinoma · peritoneal neoplasm · primary peritoneal carcinoma · primary peritoneal serous adenocarcinoma · chronic myelomonocytic leukemia
Investigated by: TetraLogic Pharmaceuticals · National Cancer Institute (NCI) · Abramson Cancer Center at Penn Medicine · Alpha Stem Cell Clinic (ASCC) · California Institute for Regenerative Medicine (CIRM) · IGM Biosciences, Inc.
+4 more
· Jonsson Comprehensive Cancer Center · Medivir · Merck Sharp & Dohme LLC · Roswell Park Cancer Institute

Trials 12 · a red edge is where a trial was stopped

today NCT04553692 · Ph 1 NCT03803774 · Ph 1 NCT02756130 · Ph 1/2 NCT02587962 · Ph 1/2 NCT02288208 · Ph 1 NCT01940172 · Ph 1 NCT01828346 · Ph 1/2 NCT01681368 · Ph 2 NCT01573780 · Ph 1 NCT01486784 · Ph 1/2 NCT01188499 · Ph 1/2 NCT00993239 · Ph 1

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT04553692	Sep 2020 → Jan 2025	acute myeloid leukemia, chondrosarcoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, colorectal cancer	IGM Biosciences, Inc.	Terminated	No outcome recorded
Phase 1	NCT03803774	Sep 2019 → Nov 2023 overdue	nasal cavity and paranasal sinus squamous cell carcinoma, nasopharyngeal squamous cell carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT02288208	Nov 2014 → May 2015	chronic hepatitis B virus infection	TetraLogic Pharmaceuticals	Terminated	No outcome recorded
Phase 1	NCT01940172	Nov 2013 → Sep 2015	fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma	TetraLogic Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01573780	Apr 2012 → Sep 2013	cancer of unknown primary site	Roswell Park Cancer Institute	Terminated	No outcome recorded
Phase 1	NCT00993239	Nov 2009 → Aug 2012	cancer	TetraLogic Pharmaceuticals	Completed	No outcome recorded
Phase 1/25 trials
Phase 1/2	NCT02756130	Aug 2018 → Feb 2020	fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma	Jonsson Comprehensive Cancer Center	Withdrawn	No outcome recorded
Phase 1/2	NCT02587962	Aug 2017 → Feb 2020	cancer	Medivir	Terminated	No outcome recorded
Phase 1/2	NCT01828346	Jun 2013 → Jun 2015	myelodysplastic syndrome	TetraLogic Pharmaceuticals	Completed	No outcome recorded
Phase 1/2	NCT01486784	Nov 2011 → Nov 2014	acute myeloid leukemia	Abramson Cancer Center at Penn Medicine	Terminated	No outcome recorded
Phase 1/2	NCT01188499	Oct 2010 → Oct 2013	cancer	TetraLogic Pharmaceuticals	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT01681368	Aug 2012 → Dec 2013	fallopian tube neoplasm, malignant epithelial tumor of ovary, peritoneal neoplasm	National Cancer Institute (NCI)	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02147873 Comparator	Jun 2014 → Jan 2016	chronic myelomonocytic leukemia, myelodysplastic syndrome	TetraLogic Pharmaceuticals	Terminated	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	Birinapant	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02288208 ↗ 11 NCT01681368 ↗ NCT02756130 ↗ NCT03803774 ↗ NCT02587962 ↗ NCT01940172 ↗ NCT01828346 ↗ NCT02147873 ↗ NCT01486784 ↗ NCT00993239 ↗ NCT04553692 ↗ NCT01188499 ↗
Known as	TL32711	“Birinapant (TL32711) is a synthetic peptidomimetic antagonist of IAPs (a SMAC-mimetic), which mimics endogenous SMAC resulting in the rapid and irreversible initiation of...” NCT01681368 ↗ 3 “PD) of birinapant (TL32711) when administered in combination with 5-azacitidine” NCT01828346 ↗ “Birinapant (TL32711)” NCT00993239 ↗ NCT01573780 ↗
Action	Inhibit	“Birinapant (TL32711) is a synthetic peptidomimetic antagonist of IAPs (a SMAC-mimetic), which mimics endogenous SMAC resulting in the rapid and irreversible initiation of...” NCT01681368 ↗
Modality	Small molecule	— CHEMBL3039522 ↗
Route	Intravenous	“30 minute intravenous infusion” NCT00993239 ↗